[Hemodynamic effects and effects on plasma renin activity of injectable acebutolol in arterial hypertension]. 1975

J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg

The purpose of the study was to determine the early haemodynamic effects of injectable acebutolol and to study in parallel the changes in plasma renin activity (P.R.A.) in 11 patients, most of whom were affected with labile arterial hypertension. The haemodynamic measurements and P.R.A. determinations were carried out before and 5 and 15 mn after very slow intravenous injection of 10 mg acebutolol. The results obtained under these conditions were as follows: 1) Decrease in cardiac index (I.C.). It was particularly significant after 5 mn, since the I.C. decreased from 4.43 to 3.75 1/mm (p less than .01). It was essentially due to a decrease in heart rate, that fell from 90.45 to 77 beats/mn (p less than .001), while stroke volume changed virtually not. 2) Decrease in blood pressure, more marked on systolic blood pressure (110 mm Hg after 15 mn as against 154 mm Hg before injection; p less than .001), associated with a decrease in left ventricular work (4.7 kgm/mn/m2 after 5 mn as against 6.2 kgm/mn/m2 before injection; p less than .001), without significant changes in total systemic arterial resistances. 3) Increase in diastolic pulmonary arterial pressure (10.4 mm Hg after 5 mn against 8.09 mm Hg before injection; p less than .001), testifying to a slight left ventricular myocardial depression. 4) Decrease in supine P.R.A. level (0.72 nanogram/1/mn after 5 mn as against 1.15 nanogram/1/min before injection; p less than .01). A significant correlation was found between this decrease in P.R.A. and that in I.C., testifying to a close parallelism between the inhibition of cardiac beta-1 receptors and that of the receptors involved in renine secretion. 5) The tolerance of injectable acebutolol appeared to us to be excellent.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001775 Blood Circulation The movement of the BLOOD as it is pumped through the CARDIOVASCULAR SYSTEM. Blood Flow,Circulation, Blood,Blood Flows,Flow, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug

Related Publications

J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
January 1975, La Nouvelle presse medicale,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
December 1975, La Nouvelle presse medicale,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
January 1969, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
December 1980, Bollettino della Societa italiana di biologia sperimentale,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
October 1973, Modern concepts of cardiovascular disease,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
January 1981, Srpski arhiv za celokupno lekarstvo,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
March 1977, Archives of internal medicine,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
January 1973, Acta medica Scandinavica. Supplementum,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
January 1994, Lijecnicki vjesnik,
J Lekieffre, and A Carré, and A Ginestet, and P Dewailly, and H Warembourg
November 1975, La Nouvelle presse medicale,
Copied contents to your clipboard!